Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$24.50 USD

24.50
1,515,321

-0.31 (-1.25%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $24.51 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Alkermes (ALKS) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Alkermes (ALKS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Has Glaukos (GKOS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Glaukos (GKOS) and Alkermes (ALKS) have performed compared to their sector so far this year.

Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?

by Zacks Equity Research

Incyte (INCY) outperforms the industry in the year so far as lead drug Jakafi maintains momentum. Pipeline progress has also been encouraging.

Reasons to Add Patterson Companies (PDCO) to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Kezar (KZR) Doubles on Promising Kidney Disorder Study Data

by Zacks Equity Research

Shares of Kezar (KZR) surge more than 100% during after-hour trading on Jun 27, following a promising data readout from a mid-stage study evaluating zetomipzomib in patients with active lupus nephritis.

Axsome (AXSM) Surges Following FDA Label Proposal for AXS-05

by Zacks Equity Research

Axsome (AXSM) receives proposed labeling from the FDA for its under-review depression drug candidate, AXS-05, implying a potential approval soon. Shares surge more than 50%.

Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation

by Zacks Equity Research

Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.

Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion

by Zacks Equity Research

Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.

Here's Why Investors Should Retain CVS Health (CVS) For Now

by Zacks Equity Research

Investors are optimistic about CVS Health's (CVS) robust revenue growth across its operating segments.

Epizyme (EPZM) Stock Surges on Acquisition Offer From Ipsen

by Zacks Equity Research

Ipsen, through its wholly-owned subsidiary, is set to acquire Epizyme (EPZM) for $1.45 per share, in cash, along with a contingent value right of $1 per share. The transaction is likely to close by third-quarter 2022.

Pfizer's (PFE) Omicron-Based COVID Shot Betters Immune Response

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech's (BNTX) Omicron-specific COVID vaccine candidates achieves a higher immune response against the variant in a phase II/III study.

Emergent's (EBS) Anthrax Vaccine BLA Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts Emergent's (EBS) BLA seeking approval for its new anthrax vaccine, AV7909. A decision is expected in April next year.

Merck (MRK) Keytruda Gets Europe Nod for Expanded Melanoma Use

by Zacks Equity Research

European Commission approves Merck's (MRK) Keytruda as an adjuvant treatment for adults and adolescent patients with stage IIB or IIC melanoma and who have undergone complete resection.

Gilead (GILD) Announces Positive Data on Hepcludex for HDV

by Zacks Equity Research

Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.

Walgreens (WBA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Robust performances across the U.S. pharmacy and retail business are likely to have contributed to Walgreens' (WBA) Q3 performance.

F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm

by Zacks Equity Research

Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.

Sarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051

by Zacks Equity Research

The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study.

Tandem Diabetes (TNDM) Global Pump Sales Aid, Price Issue Ails

by Zacks Equity Research

Tandem Diabetes (TNDM) is witnessing strong customer retention, driven by the impressive positive response from the Control-IQ technology.

Novartis' (NVS) Oncology Drugs Get Approval for Label Expansion

by Zacks Equity Research

Novartis (NVS) obtains regulatory approval for label expansion of Tafinlar + Mekinist and Tabrecta.

Here's Why You Should Retain Neogen (NEOG) Stock for Now

by Zacks Equity Research

Neogen's (NEOG) robust segmental performance and notable product launches instill investors' confidence.

Moderna (MRNA) Reveals New Data on Bivalent COVID Booster

by Zacks Equity Research

Moderna's (MRNA) bivalent COVID booster candidate exhibits a greater than a 5-fold boost in antibody responses against the Omicron subvariants BA.4 and BA.5 in a phase II/III study.

Merck's (MRK) Pneumococcal Vaccine Gets FDA Nod for Kids

by Zacks Equity Research

Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

Here's Why Investors Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors are optimistic about Tandem Diabetes' (TNDM) strong pump shipments and ongoing product innovations.

Walgreens (WBA) to Offer Health Services to Ohio Medicaid Members

by Zacks Equity Research

Walgreens' (WBA) subsidiary teams up with Buckeye Health Plan to provide wellness services through Walgreens Health Corner locations in Ohio.

National Vision (EYE) Gains on Volume Growth Amid Margin Woes

by Zacks Equity Research

National Vision (EYE) plans to continue executing its core growth initiatives and further investing in strengthening competitive advantages.